Quick Answer
Aquestive Therapeutics, Inc. reported Total Revenue of $44.55 million for fiscal year 2025.
Aquestive Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $44.55M -22.6% |
$57.56M +13.8% |
$50.58M +6.1% |
$47.68M -6.2% |
$50.83M +10.9% |
$45.85M -12.8% |
| Revenue (ASC 606) | $44.55M -22.6% |
$57.56M +13.8% |
$50.58M +6.1% |
$47.68M -6.2% |
$50.83M +10.9% |
$45.85M -12.8% |
| Net Income | -$83.78M -89.8% |
-$44.14M -460.8% |
-$7.87M +85.5% |
-$54.41M +22.9% |
-$70.54M -26.5% |
-$55.78M +15.8% |
| Diluted EPS | -$0.78 -52.9% |
-$0.51 -292.3% |
-$0.13 +88.4% |
-$1.12 +39.5% |
-$1.85 -11.4% |
-$1.66 |
| Total Assets | $160.43M +58.2% |
$101.42M +76.6% |
$57.42M +0.6% |
$57.07M -7.9% |
$61.99M -1.4% |
$62.88M -19.9% |
| Cash and Equivalents | — | — | — | — | — | $31.81M -35.5% |
| Stockholders Equity | -$33.66M +44.0% |
-$60.16M +43.5% |
-$106.49M +10.2% |
-$118.55M -44.3% |
-$82.13M -69.4% |
-$48.50M -692.2% |
| R&D Expense | $17.19M -15.2% |
$20.28M +54.8% |
$13.10M -25.0% |
$17.48M +2.5% |
$17.05M -14.3% |
$19.89M -3.3% |
| Operating Income | -$71.05M -130.9% |
-$30.77M -103.8% |
-$15.10M +64.1% |
-$42.07M -21.3% |
-$34.68M +19.1% |
-$42.89M +18.6% |
| Shares Outstanding | 122.04M +33.5% |
91.41M +33.4% |
68.53M +25.0% |
54.83M +33.0% |
41.23M +19.3% |
34.57M +3.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $12.81M | -5.4% | +28.0% |
| Revenue (ASC 606) | September 30, 2025 | $12.81M | -5.4% | +28.0% |
| Net Income | September 30, 2025 | -$15.45M | -34.2% | -14.0% |
| Diluted EPS | September 30, 2025 | -$0.14 | -7.7% | +0.0% |
| Total Assets | September 30, 2025 | $163.56M | +48.7% | +74.6% |
| Cash and Equivalents | September 30, 2025 | $129.06M | +65.7% | +113.2% |
| Stockholders Equity | September 30, 2025 | -$4.11M | +91.0% | +94.3% |
| R&D Expense | September 30, 2025 | $4.53M | -14.0% | +10.4% |
| Operating Income | September 30, 2025 | -$11.48M | -38.5% | -1.0% |
| Shares Outstanding | September 30, 2025 | 121.66M | +33.4% | +22.5% |
- Aquestive Therapeutics, Inc. reported Total Revenue of $44.55 million for fiscal year 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -22.6% in Total Revenue compared to the prior fiscal year.
- Aquestive Therapeutics, Inc. reported Revenue (ASC 606) of $44.55 million for fiscal year 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -22.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Aquestive Therapeutics, Inc. reported Net Income of -$83.78 million for fiscal year 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -89.8% in Net Income compared to the prior fiscal year.
- Aquestive Therapeutics, Inc. reported Diluted EPS of $0.78 per share (loss) for fiscal year 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -52.9% in Diluted EPS compared to the prior fiscal year.
- Aquestive Therapeutics, Inc. reported Total Assets of $160.43 million for fiscal year 2025.
- Aquestive Therapeutics, Inc. showed an increase of +58.2% in Total Assets compared to the prior fiscal year.
- Aquestive Therapeutics, Inc. reported Cash and Equivalents of $31.81 million for fiscal year 2020.
- Aquestive Therapeutics, Inc. showed a decrease of -35.5% in Cash and Equivalents compared to the prior fiscal year.
- Aquestive Therapeutics, Inc. reported Stockholders Equity of -$33.66 million for fiscal year 2025.
- Aquestive Therapeutics, Inc. showed an increase of +44.0% in Stockholders Equity compared to the prior fiscal year.
- Aquestive Therapeutics, Inc. reported R&D Expense of $17.19 million for fiscal year 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -15.2% in R&D Expense compared to the prior fiscal year.
- Aquestive Therapeutics, Inc. reported Operating Income of -$71.05 million for fiscal year 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -130.9% in Operating Income compared to the prior fiscal year.
- Aquestive Therapeutics, Inc. reported Shares Outstanding of 122.04 million shares for fiscal year 2025.
- Aquestive Therapeutics, Inc. showed an increase of +33.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: